We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

The FTC, Reverse Payments In The Obama Era

Law360 (May 15, 2009, 12:00 AM EDT) -- An impasse is looming in the pharmaceutical industry, and it is poised to provide insight into the approach that the Obama administration takes to antitrust regulation and enforcement.

On one hand, the Federal Trade Commission is taking aim at pharmaceutical companies that settle drug patent litigation on terms that allow the brand company to preserve its monopoly by paying the generic company to drop its patent challenge and take a fixed date of market entry.

On the other hand, private companies want to have the freedom...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.